NCT00805415 - Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens | Biotech Hunter

Enrollment

209

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions

Ovulation Inhibition

Interventions

DRUG

EV/DNG (Qlaira, BAY86-5027, SH T00658K)

Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg

DRUG

EV/DNG (SH T00658L)

Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg

Trial Locations (2)

Dinox GmbH Berlin, Berlin

Dinox B.V., Groningen